Terms: = Gastric cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1
333 results:
1. First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an vegfr-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study.
Chen X; Xu H; Chen X; Xu T; Tian Y; Wang D; Guo F; Wang K; Jin G; Li X; Wang R; Li F; Ding Y; Tang J; Fang Y; Zhao J; Liu L; Ma L; Meng L; Hou Z; Zheng R; Liu Y; Guan N; Zhang B; Tong S; Chen S; Li X; Shu Y
Signal Transduct Target Ther; 2024 Mar; 9(1):73. PubMed ID: 38528050
[TBL] [Abstract] [Full Text] [Related]
2. The pathological roles and potential mechanisms of vascular endothelial growth factor receptor-3 in gastric cancer.
Li XF; Zhang XJ; Hao FR; Dong XT; Xu GD; Zhang YX
J Int Med Res; 2024 Mar; 52(3):3000605241234558. PubMed ID: 38518198
[TBL] [Abstract] [Full Text] [Related]
3. Recent development of vegfr small molecule inhibitors as anticancer agents: A patent review (2021-2023).
Zeng J; Deng Q; Chen Z; Yan S; Dong Q; Zhang Y; Cui Y; Li L; He Y; Shi J
Bioorg Chem; 2024 May; 146():107278. PubMed ID: 38484586
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Masetti M; Al-Batran SE; Goetze TO; Thuss-Patience P; Knorrenschild JR; Goekkurt E; Folprecht G; Ettrich TJ; Lindig U; Luley KB; Pink D; Dechow T; Sookthai D; Junge S; Loose M; Pauligk C; Lorenzen S
Int J Cancer; 2024 Jun; 154(12):2142-2150. PubMed ID: 38447003
[TBL] [Abstract] [Full Text] [Related]
5. Advances in targeted therapy for gastric cancer based on tumor driver genes.
Wu S; Xu P; Zhang F
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Feb; 53(1):73-83. PubMed ID: 38413217
[TBL] [Abstract] [Full Text] [Related]
6. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer.
Arai H; Yang Y; Baca Y; Millstein J; Denda T; Ou FS; Innocenti F; Takeda H; Kubota Y; Doi A; Horie Y; Umemoto K; Izawa N; Wang J; Battaglin F; Jayachandran P; Algaze S; Soni S; Zhang W; Goldberg RM; Hall MJ; Scott AJ; Hwang JJ; Lou E; Weinberg BA; Marshall J; Goel S; Xiu J; Michael Korn W; Venook AP; Sunakawa Y; Lenz HJ
Eur J Cancer; 2024 Apr; 201():113914. PubMed ID: 38359495
[TBL] [Abstract] [Full Text] [Related]
7. Regulation of regulatory T cells and tumor-associated macrophages in gastric cancer tumor microenvironment.
Shaopeng Z; Yang Z; Yuan F; Chen H; Zhengjun Q
Cancer Med; 2024 Jan; 13(2):e6959. PubMed ID: 38349050
[TBL] [Abstract] [Full Text] [Related]
8. PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
Gou M; Zhang Y; Wang Z; Qian N; Dai G
Invest New Drugs; 2024 Apr; 42(2):171-178. PubMed ID: 38347177
[TBL] [Abstract] [Full Text] [Related]
9. Rivoceranib, a vegfr-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial.
Kang YK; Ryu MH; Di Bartolomeo M; Chau I; Yoon H; Kim JG; Lee KW; Oh SC; Takashima A; Kryzhanivska A; Chao Y; Evesque L; Schenker M; McGinn A; Zhao Y; Lee J; Wyrwicz L; Boku N
Gastric Cancer; 2024 Mar; 27(2):375-386. PubMed ID: 38281295
[TBL] [Abstract] [Full Text] [Related]
10. Clinical Management of gastric cancer Treatment Regimens.
Boilève J; Touchefeu Y; Matysiak-Budnik T
Curr Top Microbiol Immunol; 2023; 444():279-304. PubMed ID: 38231223
[TBL] [Abstract] [Full Text] [Related]
11. gastric tubular adenocarcinoma with diffuse neutrophils infiltrating: characteristics and probable treatment strategy.
Wang B; Zhu Y; Wang S; Li Z; Wang L; Rao W; Cheng N; Chen R; Ying J; Xue L
Gastric Cancer; 2024 Jan; 27(1):86-101. PubMed ID: 38019350
[TBL] [Abstract] [Full Text] [Related]
12. Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer.
Hyung S; Ko J; Heo YJ; Blum SM; Kim ST; Park SH; Park JO; Kang WK; Lim HY; Klempner SJ; Lee J
Sci Adv; 2023 Nov; 9(47):eadk1098. PubMed ID: 38000030
[TBL] [Abstract] [Full Text] [Related]
13. PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis.
Hu J; Hameed MR; Agaram NP; Whiting KA; Qin LX; Villano AM; O'Connor RB; Rozenberg JM; Cohen S; Prendergast K; Kryeziu S; White RL; Posner MC; Socci ND; Gounder MM; Singer S; Crago AM
Clin Cancer Res; 2024 Jan; 30(2):450-461. PubMed ID: 37943631
[TBL] [Abstract] [Full Text] [Related]
14. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
15. Genomic and Transcriptomic Characterization of gastric cancer with Bone Metastasis.
Oh S; Nam SK; Lee KW; Lee HS; Park Y; Kwak Y; Lee KS; Kim JW; Kim JW; Kang M; Park YS; Ahn SH; Suh YS; Park DJ; Kim HH
Cancer Res Treat; 2024 Jan; 56(1):219-237. PubMed ID: 37591783
[TBL] [Abstract] [Full Text] [Related]
16. [Skip metastasis at the esophageal resection margin in radical gastrectomy: clinical characteristics of 30 cases].
Liu S; Xia QY; Fu Y; Lu XF; Wang M; Guan WX
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jul; 26(7):675-679. PubMed ID: 37583025
[No Abstract] [Full Text] [Related]
17. Solute carrier family 35 member A2 (SLC35A2) is a prognostic biomarker and correlated with immune infiltration in stomach adenocarcinoma.
Huang Z; Yang H; Lao J; Deng W
PLoS One; 2023; 18(7):e0287303. PubMed ID: 37467193
[TBL] [Abstract] [Full Text] [Related]
18. The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art.
Lu G; Wang X; Cheng M; Wang S; Ma K
Biomed Pharmacother; 2023 Sep; 165():115132. PubMed ID: 37423169
[TBL] [Abstract] [Full Text] [Related]
19. Anthracycline chemicals with anthracyclinone structure exert antitumor effects by inhibiting angiogenesis and lymphangiogenesis in a xenografted gastric tumor model.
Li H; Jia C; Li C; Wang Y; Du W; Jiang H
Gastric Cancer; 2023 Nov; 26(6):863-877. PubMed ID: 37344705
[TBL] [Abstract] [Full Text] [Related]
20. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.
Li J; Qin S; Wen L; Wang J; Deng W; Guo W; Jia T; Jiang D; Zhang G; He Y; Ba Y; Zhong H; Wang L; Lin X; Yang J; Zhao J; Bai Y; Wu X; Gao F; Sun G; Wu Y; Ye F; Wang Q; Xie Z; Yi T; Huang Y; Yu G; Lu L; Yuan Y; Li W; Liu L; Sun Y; Sun Y; Yin L; Hou Z
BMC Med; 2023 May; 21(1):173. PubMed ID: 37147645
[TBL] [Abstract] [Full Text] [Related]
[Next]
